PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application.

Cancer stem cells (CSCs) are a subpopulation of tumor cells that possess unique self-renewal activity and mediate tumor initiation and propagation. The PI3K/Akt/mTOR signaling pathway can be considered as a master regulator for cancer. More and more recent studies have shown the links between PI3K/Akt/mTOR signaling pathway and CSC biology. Herein, we provide a comprehensive review on the role of signaling components upstream and downstream of PI3K/Akt/mTOR signaling in CSC. In addition, we also summarize various classes of small molecule inhibitors of PI3K/Akt/mTOR signaling pathway and their clinical potential in CSC. Overall, the current available data suggest that the PI3K/Akt/mTOR signaling pathway could be a promising target for development of CSC-target drugs.

[1]  J. Testa,et al.  Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. , 2004, Carcinogenesis.

[2]  Chen-Yang Shen,et al.  PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.

[3]  William A Weiss,et al.  Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. , 2012, Methods in molecular biology.

[4]  C. Porta,et al.  Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..

[5]  E. Cuyás,et al.  Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway , 2013, Cell cycle.

[6]  J. Wang-Rodriguez,et al.  Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt , 2012, BMC Cancer.

[7]  K. Shen,et al.  PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer , 2014, Archives of Gynecology and Obstetrics.

[8]  B. Katzenellenbogen,et al.  The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells , 2014, Breast Cancer Research.

[9]  G. Opelz,et al.  Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. , 2009, Biochemical and biophysical research communications.

[10]  J. Ajani,et al.  Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer , 2014, International journal of oncology.

[11]  E. Bellolio,et al.  The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance , 2014, Virchows Archiv.

[12]  Tatsuya Ozawa,et al.  PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. , 2009, Cell stem cell.

[13]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[14]  S. Shankar,et al.  Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: molecular mechanisms , 2013, Molecular Cancer.

[15]  Mayumi Horie,et al.  Branched Chain Amino Acid Suppresses Hepatocellular Cancer Stem Cells through the Activation of Mammalian Target of Rapamycin , 2013, PloS one.

[16]  P. Horák,et al.  HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells , 2014, Molecular Cancer Research.

[17]  P. Schultz,et al.  Combination Therapy Targeting Both Tumor-Initiating and Differentiated Cell Populations in Prostate Carcinoma , 2010, Clinical Cancer Research.

[18]  Z. Qin,et al.  NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro , 2013, Acta Pharmacologica Sinica.

[19]  Biological characteristics of CD133(+) cancer stem cells derived from human laryngeal carcinoma cell line. , 2014, International journal of clinical and experimental medicine.

[20]  J. McCubrey,et al.  Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment , 2012, Oncotarget.

[21]  J. Cheng,et al.  Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas , 1998, Molecular carcinogenesis.

[22]  Tao Zhang,et al.  Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. , 2009, Cancer research.

[23]  P. Schultz,et al.  The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations , 2009, Proceedings of the National Academy of Sciences.

[24]  T. Kang,et al.  Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. , 2011, Cancer letters.

[25]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[26]  R. Gu,et al.  PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity , 2013, Medical Oncology.

[27]  J. Margolick,et al.  Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance , 2007, Proceedings of the National Academy of Sciences.

[28]  N. Wong,et al.  Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133 , 2014, Oncotarget.

[29]  J. Cheng,et al.  Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Gil-Ranedo,et al.  Efficacy of rapamycin against glioblastoma cancer stem cells , 2014, Clinical and Translational Oncology.

[31]  Temsirolimus for advanced renal cell carcinoma. , 2007, Clinical advances in hematology & oncology : H&O.

[32]  Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors , 2011, Clinical Cancer Research.

[33]  N. Saijo,et al.  mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. , 2009, Cancer research.

[34]  J. Christensen,et al.  Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation , 2013, PloS one.

[35]  D. Gilliland,et al.  Drug therapy for acute myeloid leukemia. , 2005, Blood.

[36]  J. Jung,et al.  Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells , 2013, Oncogene.

[37]  Z. Kozovska,et al.  Colon cancer: cancer stem cells markers, drug resistance and treatment. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[38]  Arata Tomiyama,et al.  Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self‐Renewal and Tumorigenicity of Glioblastoma Stem‐Like Cells , 2010, Stem cells.

[39]  R. Beaulieu,et al.  ALDH1 as a functional marker of cancer stem and progenitor cells. , 2009, Stem cells and development.

[40]  Yi Wang.  Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. , 2011, Medicinal chemistry (Shariqah (United Arab Emirates)).

[41]  Kevin Struhl,et al.  Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. , 2009, Cancer research.

[42]  Q. Gong,et al.  Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation. , 2011, Carcinogenesis.

[43]  Kevin Struhl,et al.  Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. , 2011, Cancer research.

[44]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[45]  E. Lagasse,et al.  Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1 , 2013, Oncotarget.

[46]  Lequn Li,et al.  Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. , 2014, World journal of gastroenterology.

[47]  K. Alitalo,et al.  [Prox1 promotes expansion of the colorectal cancer stem cell population to fuel tumor growth and ischemia resistance]. , 2014, Duodecim; laaketieteellinen aikakauskirja.

[48]  J. Dutcher,et al.  Temsirolimus for advanced renal cell carcinoma (RCC): Compassionate versus commercial use , 2008 .

[49]  S. Zhang,et al.  Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study , 2014, Tumor Biology.

[50]  J. Baselga,et al.  TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. , 2010, Cancer cell.

[51]  S. Staal.  Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Pu Xia.  Surface markers of cancer stem cells in solid tumors. , 2014, Current stem cell research & therapy.

[53]  S. Hung,et al.  Silibinin suppresses the maintenance of colorectal cancer stem‐like cells by inhibiting PP2A/AKT/mTOR pathways , 2012, Journal of cellular biochemistry.

[54]  J. Mao,et al.  Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells. , 2013, Biochemical and biophysical research communications.

[55]  Ruud P. M. Dings,et al.  Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells , 2012, Scientific Reports.

[56]  E. Boscolo,et al.  Rapamycin Suppresses Self-Renewal and Vasculogenic Potential of Stem Cells Isolated from Infantile Hemangioma , 2011, The Journal of investigative dermatology.

[57]  J. Moffat,et al.  CD133 Protein N-Glycosylation Processing Contributes to Cell Surface Recognition of the Primitive Cell Marker AC133 Epitope* , 2011, The Journal of Biological Chemistry.

[58]  Xiaoping Chen,et al.  Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. , 2013, Cancer letters.

[59]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[60]  L. Tang,et al.  Cyclin G1 Expands Liver Tumor-Initiating Cells by Sox2 Induction via Akt/mTOR Signaling , 2013, Molecular Cancer Therapeutics.

[61]  A. Ullrich,et al.  Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status , 2014, Oncotarget.

[62]  H. Cui,et al.  Neurotensin signaling regulates stem-like traits of glioblastoma stem cells through activation of IL-8/CXCR1/STAT3 pathway. , 2014, Cellular signalling.

[63]  Jyh‐cherng Yu,et al.  The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors , 2013, Breast Cancer Research.

[64]  D. Teachey,et al.  Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies , 2014, Front. Oncol..

[65]  V. Steele,et al.  Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. , 2013, Translational oncology.

[66]  J. Curtin,et al.  Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells , 2010, Oncotarget.

[67]  S. Zhang,et al.  Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo , 2012, Tumor Biology.

[68]  Jianren Gu,et al.  Transient mTOR Inhibition Facilitates Continuous Growth of Liver Tumors by Modulating the Maintenance of CD133+ Cell Populations , 2011, PloS one.

[69]  S. Shankar,et al.  Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells. , 2012, Biochemical pharmacology.

[70]  Yong Li,et al.  Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance , 2013, Cell Death and Disease.

[71]  Chang-Shin Park,et al.  Response of Breast Cancer Cells and Cancer Stem Cells to Metformin and Hyperthermia Alone or Combined , 2014, PloS one.

[72]  S. Shankar,et al.  Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway. , 2014, Cancer letters.

[73]  F. Marks,et al.  Rottlerin, a novel protein kinase inhibitor. , 1994, Biochemical and biophysical research communications.

[74]  W. De,et al.  Histone Deacetylase 1/Sp1/MicroRNA-200b Signaling Accounts for Maintenance of Cancer Stem-Like Cells in Human Lung Adenocarcinoma , 2014, PloS one.

[75]  M. Zheng,et al.  Salinomycin Selectively Targets ‘CD133+’ Cell Subpopulations and Decreases Malignant Traits in Colorectal Cancer Lines , 2011, Annals of Surgical Oncology.

[76]  F. Mahon,et al.  PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor , 2013, Cell Death and Disease.